Search Results for “EC” – Page 241 – media

Existing drug alleviates symptoms of a rare genetic syndrome

A drug approved to treat certain autoimmune diseases and cancers successfully alleviated symptoms of a rare genetic syndrome called autoimmune polyendocrine syndrome type 1 (APS-1). Researchers identified the treatment based on their discovery that the syndrome is linked to elevated levels of interferon-gamma (IFN-gamma), a protein involved in immune system responses, providing new insights into the role of IFN-gamma in autoimmunity. The study, led by researchers at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, was published today in the New England Journal of Medicine. In a three-stage study, conducted in mice and people, the researchers examined how APS-1 causes autoimmune disease. The syndrome is marked by dysfunction of multiple organs, usually beginning in childhood, and is fatal in more than 30% of cases. This inherited syndrome is caused by a deficiency in a gene that keeps the immune system’s T cells from attacking cells of ...
- Source: drugdu
- 110
- June 3, 2024
Better sleep health associated with lower levels of loneliness

A new study to be presented at the SLEEP 2024 annual meeting found that better sleep health was associated with lower levels of loneliness, and this association was stronger among younger adults. Results indicate that better sleep health was associated with significantly lower total loneliness, emotional loneliness and social loneliness. While better sleep health was associated with lower total and emotional loneliness across ages, this association was stronger for younger adults. However, age did not moderate the association between sleep health and social loneliness. “Loneliness is an urgent public health crisis, and there is a pressing need for providers to better understand and treat it,” said lead author and principal investigator Joseph Dzierzewski, who has a doctorate in clinical psychology and is vice president of research at the National Sleep Foundation in Washington, D.C. “Our results highlight the important role that sleep plays in understanding loneliness across the adult lifespan. ...
- Source: drugdu
- 80
- June 3, 2024
The University of Macau and Sinopharm Group signed a cooperation agreement to carry out biopharmaceutical cooperation

According to the University of Macau (UM) on the 4th, in order to cooperate with the Macao Special Administrative Region Government’s “1+4” moderate economic diversification development strategy and promote the development of Macao’s big health industry, UM and China National Pharmaceutical Group Co., Ltd. (Sinopharm Group) recently signed a strategic cooperation agreement in the field of big health. Both parties hope to promote the transformation of Australia’s scientific research results through closer industry-university-research cooperation, and help enhance the scientific and technological strength of the biomedicine and health strategy. Liu Jingzhen, Chairman of China National Pharmaceutical Group Co., Ltd., led a delegation to visit the University of Adelaide on February 26. The delegation members included leaders of Sinopharm Group and representatives of subsidiaries in different fields such as traditional Chinese medicine , biopharmaceuticals, chemical pharmaceuticals, and medical aesthetics. UM Rector Yonghua Song briefed the delegation on UM’s recent development, strengths and ...
- Source: drugdu
- 110
- June 3, 2024
NHS announces hospitals will roll out ‘Martha’s Rule’ as part of patient safety initiative

The first phase of the programme will be in place in hospitals across the UK by March 2025 The NHS has announced the roll out of Martha’s Rule across 143 hospital sites across the UK to test its implementation as part of a major patient safety initiative by March 2025. The scheme is named after Martha Mills, who passed away from sepsis at age 13 in 2021 due to a failure to escalate her to intensive care, while her family’s concerns about her condition were not responded to. The aim of Martha’s Rule is to provide a consistent and understandable way for patients and families to seek an urgent review if either their or their loved one’s condition deteriorates and they are concerned this is not being responded to. The rule is made up of three components: firstly, an escalation process will be available 24/7 to enable patients and families ...
- Source: drugdu
- 114
- June 3, 2024
Researchers identify genetic changes responsible for rare childhood immune disorders

Affecting the immune system, various forms of SCID are estimated to affect one in 75,000 to 100,000 newborns A new study led by Newcastle University has identified the genetic changes that are responsible for rare childhood immune disorders that can leave newborns with little to no immune defence against infections. Published in Science Immunology, the study involved experts from the Great North Children’s Hospital, the Wellcome Sanger Institute and their collaborators. Severe combined immunodeficiency (SCID) and Omenn syndrome are two rare genetic disorders that affect the function of children’s immune systems and put them at risk of life-threatening conditions. While the prevalence of Omenn syndrome is unknown, the various forms of SCID are estimated to affect one in 75,000 to 100,000 newborns. Without urgent treatment, including stem cell transplants to replace the faulty immune system, most children affected will not survive their first year of life. Researchers studied 11 children, ...
- Source: drugdu
- 90
- June 3, 2024
FDA Grants Priority Review to Jazz Pharmaceuticals’ Zanidatamab for Multiple Forms of HER-2 Positive Biliary Tract Cancer

Don Tracy, Associate Editor Submission for the FDA approval of zanidatamab was based on promising data from the Phase IIb HERIZON-BTC-01 clinical trial in patients with previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer. Jazz Pharmaceuticals announced that the FDA has granted Priority Review to zanidatamab, a bispecific antibody being evaluated for previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). According to the company, the submission was based on positive results from Cohort 1 of the Phase IIb HERIZON-BTC-01 clinical trial, which showed a confirmed objective response rate (cORR) of 41.3%. The FDA assigned the application with a Prescription Drug User Fee Act target action date of November 29, 2024. A Phase III trial, HERIZON-BTC-302, is evaluating zanidatamab in combination with standard-of-care therapy against standard-of-care therapy alone in first-line advanced or metastatic HER2-positive BTC.1 “The priority review designation for zanidatamab underscores the critical ...
- Source: drugdu
- 103
- June 3, 2024
FDA Approves Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

Davy James Breyanzi, a CD19-directed CAR T-cell therapy, granted fourth FDA approval to treat a distinct subtype of non-Hodgkin lymphoma.The FDA has approved Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel) to treat adults with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who were previously administered at least two lines of systemic therapy that included a Bruton tyrosine kinase (BTK) inhibitor.1 The regulatory action marks the fourth indication for Breyanzi to treat a distinct subtype of non-Hodgkin lymphoma. “With Breyanzi, we are delivering on the promise of cell therapy by offering a definitive treatment option for some of the most difficult-to-treat lymphomas,” Bryan Campbell, senior vice president, head of Commercial, Cell Therapy, BMS, said in a press release. “We are proud of the advances we are making to bring our differentiated CAR T cell therapy to the most patients across indications and lines of therapy to ensure treatment options that ...
- Source: drugdu
- 92
- June 3, 2024
BHF awards £35m funding to nine UK universities for cardiovascular disease

Affecting more than 7 million people in the UK, cardiovascular diseases are conditions that affect the heart or circulation The British Heart Foundation (BHF) has awarded a total of £35m in funding to nine universities across the UK to help strengthen world-leading cardiovascular disease research. Provided through BHF’s Research Excellence Awards scheme, the funding will support research environments that encourage collaboration, inclusion and innovation to accelerate lifesaving breakthroughs. Affecting around 7.6 million people in the UK, cardiovascular disease is a term for conditions that affect the heart or circulation, including high blood pressure, stroke, heart disease and vascular dementia. The nine universities to receive part of the funding include Imperial College London (ICL), King’s College London (KCL), the University of Cambridge, Edinburgh, Leeds, Leicester, Manchester, Oxford and University College London. For the next five years, the funding will enable cutting-edge research to address some of the biggest cardiovascular disease challenges, ...
- Source: drugdu
- 115
- June 1, 2024
Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition

Merck’s EyeBio acquisition brings a lead program ready for pivotal testing in diabetic macular edema. The therapy could pose competition to Eylea, the blockbuster Regeneron Pharmaceuticals eye drug. By Frank VinluanMerck is on the hunt for drugs with blockbuster potential to make up for declining revenue when its top product, the cancer immunotherapy Keytruda, loses patent protection in the next few years. The pharmaceutical giant is getting a contender through the acquisition of a clinical-stage startup whose lead program is on track to begin pivotal testing in diabetic macular edema. According to deal terms announced Wednesday, Merck is acquiring Eyebiotech Limited, or EyeBio, for $1.3 billion in cash up front. Shareholders of the New York-based company could receive up to $1.7 billion more in milestone payments. EyeBio develops drug for retinal conditions in which inflammation leads to the breakdown of the inner blood-retinal barrier. This breakdown leads to vascular leakage, ...
- Source: drugdu
- 96
- June 1, 2024
Tianjin establishes health care group to create a new model for health care industry

The reporter learned from the Tianjin State-owned Assets Supervision and Administration Commission that Tianjin Health and Elderly Care Group Co., Ltd. (hereinafter referred to as Health and Elderly Care Group), a Class II commercial enterprise directly supervised by the commission, was recently established and put into operation. It is promoting the high-quality and coordinated development of the health and elderly care industry by exploring the parallel path of providing market-oriented mid- to high-end health and elderly care services and inclusive elderly care services supported by government policies. According to reports, Kangyang Group is positioned as the main body of investment, operation and implementation of Tianjin’s health and elderly care industry, with the integration of medical care and elderly care as its core, based on “health, medical care, health, elderly care and integration”, covering home, community, institutions and other fields, and will serve the Beijing-Tianjin-Hebei region through market-oriented methods, facing the ...
- Source: drugdu
- 102
- June 1, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.